Pharmacokinetic interaction between verapamil and everolimus in healthy subjects
Open Access
- 1 October 2005
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 60 (4), 434-437
- https://doi.org/10.1111/j.1365-2125.2005.02434.x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Everolimus Therapeutic Concentration Range Defined from a Prospective Trial with Reduced-Exposure Cyclosporine in De Novo Kidney TransplantationTherapeutic Drug Monitoring, 2004
- Everolimus: A proliferation signal inhibitor targeting primary causes of allograft dysfunctionDrugs of Today, 2004
- The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA PerspectiveThe Journal of Clinical Pharmacology, 2003
- Role of P-Glycoprotein in PharmacokineticsClinical Pharmacokinetics, 2003
- Pharmacokinetic and Pharmacodynamic Assessments of HMG‐CoA Reductase Inhibitors When Coadministered with EverolimusThe Journal of Clinical Pharmacology, 2002
- High‐throughput semi‐automated 96‐well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus (RAD 001) and cyclosporin a (CsA) in whole bloodRapid Communications in Mass Spectrometry, 2001
- Dose of midazolam should be reduced during diltiazem and verapamil treatments.British Journal of Clinical Pharmacology, 1994
- Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosingEuropean Journal of Clinical Pharmacology, 1984